Amgen licenses cancer MAb from IMMU

Immunomedics (IMMU) granted AMGN rights to develop and market in

Read the full 109 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE